Log In
BCIQ
Print this Print this
 

SJ-815

  Manage Alerts
Collapse Summary General Information
Company SillaJen Inc.
Description 
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat solid cancers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today